Achievement of Complete Response and Drug-Free Status by Atezolizumab plus Bevacizumab Combined with or without Curative Conversion in Patients with Transarterial Chemoembolization-Unsuitable, Intermediate-Stage Hepatocellular Carcinoma: A Multicenter Proof-Of-Concept Study.

"Conflict of Interest Statement Masatoshi Kudo received lecture fee from Eli Lilly, Bayer, Eisai, Chugai, Takeda, and MSD; and grants from Gilead Sciences, Taiho, Sumitomo Dainippon Pharma, Takeda, Otsuka, EA Pharma, AbbVie, Eisai, Chugai, and GE Healthcare. Masatoshi Kudo is the editor-in-chief of Liver Cancer. Tomoko Aoki, Kazuomi Ueshima, Masahiro Morita, Hirokazu Chishina, Masahiro Takita, Satoru Hagiwara, Yasunori Minami, Hiroshi Ida, Naoshi Nishida (Smoking Research Foundation [Research Grant] Chikara Ogawa), Tetsu Tomonari, Noriaki Nakamura, Hidekatsu Kuroda, Atsushi Takebe, Yoshifumi Takeyama, Masaaki Hidaka, and Susumu Eguchi had no conflict of interest. Kaoru Tsuchiya received lecture fee from Eli Lilly, Bayer, Eisai, Chugai, and Takeda. Stephan L Chan is the advisor for Astra-Zeneca, MSD, Eisai, and Ipsen, and received research funding from Bayer, Eisai, Ipsen, Sirtex, and MSD. Masayuki Kurosaki received lecture fee from Gilead, AbbVie, Eli Lilly, Bayer, Eisai, Chugai, Janssen, and Otsuka. Namiki Izumi received lecturer fee from Chugai, Eisai, Takeda, Lily, and Bayer."

"There is no funding for this study."